Drug intelligence / Profile preview

Paracetamol + codeine

Development stage
Approved
Modality
Small Molecules
Administration
Oral
01

Overview

Paracetamol + codeine is a fixed-dose combination analgesic containing paracetamol (also known as acetaminophen) and the opioid analgesic codeine phosphate. It is used for the relief of mild to moderate pain when treatment with paracetamol or non-steroidal anti-inflammatory drugs alone is insufficient[5][8]. Paracetamol acts centrally to inhibit prostaglandin synthesis, reducing pain and fever, while codeine acts on the central nervous system as a weak opioid agonist at mu-opioid receptors, providing additional analgesia[1][3][5]. The combination offers greater pain relief than either agent alone, particularly in postoperative settings[8]. Prolonged use of codeine can lead to dependence; paracetamol overdose can cause severe liver damage[2][3].

Brand names
Tylenol with CodeineTylenol with Codeine No. 3Tylenol with Codeine No. 4APAP w/CodeineCapital w/CodeinePyregesic-CVopacpms-Acetaminophen with CodeineTeva-EMTEC-30Teva-EMTEC30Teva-EMTEC 30Teva-Lenoltec No. 4Triatec-30Triatec30Triatec 30
Other names
acetaminophen and codeine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Paracetamol + codeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paracetamol + codeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call